Pauthner Matthias, Yeung Jenny, Ullman Chris, Bakker Joost, Wurch Thierry, Reichert Janice M, Lund-Johansen Fridtjof, Bradbury Andrew R M, Carter Paul J, Melis Joost P M
a Department of Immunology and Microbiology , The Scripps Research Institute , La Jolla , USA.
b University College London , London , UK.
MAbs. 2016;8(3):617-52. doi: 10.1080/19420862.2016.1153211.
The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015. The latest innovations and advances in antibody research and development were discussed, covering a myriad of antibody-related topics by more than 100 speakers, who were carefully selected by The Antibody Society. As a prelude, attendees could join the pre-conference training course focusing, among others, on the engineering and enhancement of antibodies and antibody-like scaffolds, bispecific antibody engineering and adaptation to generate chimeric antigen receptor constructs. The main event covered 4 d of scientific sessions that included antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, building comprehensive IgVH-gene repertoires through discovering, confirming and cataloging new germline IgVH genes, and overcoming resistance to clinical immunotherapy. The Antibody Society's special session focused on "Antibodies to watch" in 2016. Another special session put the spotlight on the limitations of the new definitions for the assignment of antibody international nonproprietary names introduced by the World Health Organization. The convention concluded with workshops on computational antibody design and on the promise and challenges of using next-generation sequencing for antibody discovery and engineering from synthetic and in vivo libraries.
第26届抗体工程与治疗学会议，即抗体协会的年会，于2015年12月6日至10日在圣地亚哥汇聚了来自世界各地的800多名参会者。会议讨论了抗体研发方面的最新创新和进展，100多位由抗体协会精心挑选的演讲者涵盖了众多与抗体相关的主题。作为前奏，参会者可以参加会前培训课程，该课程尤其聚焦于抗体及抗体样支架的工程改造与增强、双特异性抗体工程以及生成嵌合抗原受体构建体的适配。主要活动涵盖了为期4天的科学会议，内容包括抗体效应功能、研究和诊断抗体的可重复性、抗体药物偶联物（ADC）的新进展、临床前和临床ADC数据、双特异性抗体的新技术与应用、非癌症和罕见病适应症的抗体治疗、利用细胞免疫系统的抗体、通过发现、确认和编目新的种系IgVH基因构建全面的IgVH基因库，以及克服临床免疫疗法的耐药性。抗体协会的特别会议聚焦于2016年“值得关注的抗体”。另一场特别会议则突出了世界卫生组织引入的抗体国际非专利名称指定新定义的局限性。会议最后举办了关于计算抗体设计以及利用下一代测序从合成文库和体内文库进行抗体发现与工程改造的前景与挑战的研讨会。
